预防疫苗市场按疫苗类型、疾病类型、分销管道和地区划分

2025 年全球预防疫苗市场规模估计为 554.1 亿美元，预计到 2032 年将达到 1,073.5 亿美元，2025 年至 2032 年的复合年增长率为 9.9%。

数字。 2025 年预防疫苗市场占有率（按地区划分）

由于世界各地各种感染疾病负担加重，全球预防疫苗市场正经历成长期。预防疫苗是增强对特定疾病的免疫力并有助于预防未来感染的生技药品。多年来，疫苗学的各种进步使得疫苗的开发能够保护个人免受危及生命的疾病的侵害。此外，人们对疫苗接种认识的不断提高和疫苗技术的不断创新正在刺激对预防疫苗的需求。一些政府已经实施了国家疫苗接种计划以扩大覆盖率。此外，公共和私人医疗保健在感染疾病的支出增加也促进了预防疫苗市场的扩大。然而，开发新疫苗所涉及的高昂研发成本以及低收入国家缺乏认知是阻碍市场成长的一些因素。

市场动态

全球预防疫苗市场的成长主要受到目标感染疾病流行率不断上升的推动。新兴市场中与细菌和病毒感染相关的大量未满足的医疗需求正在推动对免疫接种和疫苗接种计划的需求。各国政府和非营利组织为加强疫苗接种计画所做的各种努力正在促进预防性疫苗的接种。例如，印度的国家免疫计划旨在免费提供针对12种危及生命的疾病的疫苗。免疫抗原性和稳定性提高的疫苗产品开发技术进步正在开启新的成长机会。然而，预计在预测期内，与新疫苗研发、测试、临床试验和製造相关的高成本将在一定程度上抑制市场扩张。人们越来越重视开发联合疫苗以降低疫苗接种成本，这将在未来几年提供有利可图的机会。

研究的主要特点

• 本报告对全球预防疫苗市场进行了详细分析，并展示了预测期（2025-2032 年）的市场规模（十亿美元）和年复合成长率（CAGR%），以 2024 年为基准年。
• 它还强调了各个领域的潜在商机并解释了该市场的有吸引力的投资提案矩阵。
• 它还提供了对市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
• 报告根据公司亮点、产品系列、关键亮点、财务表现和策略等参数，涵盖了全球预防疫苗市场的主要企业概况。
• 本报告的见解将使负责人和企业经营团队能够就未来产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
• 全球预防疫苗市场迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 透过全球预防疫苗市场分析中使用的各种策略矩阵，相关人员将发现决策更加容易。

目录

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要
• 一致的机会图 (COM)

第三章市场动态、法规与趋势分析

• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 影响分析
• 市场趋势
• 监管情景
• 管道分析
• 流行病学
• 定价和品牌分析
• 製造商收益
• 收购和合作场景
• 产品发布/核准
• 资金筹措和投资
• PEST分析
• 波特的分析

4. 全球预防疫苗市场-冠状病毒（COVID-19）大流行的影响

• 整体影响
• 政府倡议
• COVID-19 市场影响

5. 2020-2032 年全球预防疫苗市场（按疫苗类型划分）（十亿美元）

• 介绍
• 活病毒疫苗/减毒疫苗
• 灭活疫苗
• 次单位疫苗
• 类毒素疫苗
• 其他的

6. 2020-2032 年全球预防疫苗市场（按疾病类型划分）（十亿美元）

• 介绍
• 肺炎链球菌
• 脊髓灰质炎
• 肝炎
• 流感
• 麻疹
• 德国麻疹
• 其他的

7. 2020-2032 年全球预防疫苗市场按分销管道划分（十亿美元）

• 介绍
• 公共
• 私人的

8. 2020-2032 年全球预防疫苗市场（按地区划分）（单位：十亿美元）

• 介绍
• 北美洲
• 拉丁美洲
• 欧洲
• 亚太地区
• 中东
• 非洲

第九章 竞争格局

• 公司简介
  • Sanofi
  • Pfizer Inc.
  • Merck &Co. Inc.
  • GSK plc.
  • Takeda Pharmaceutical Company Limited
  • AstraZeneca
  • Daiichi Sankyo Co. Ltd.
  • Emergent BioSolutions Inc.
  • Novavax Inc.
  • Zydus Group
  • Moderna, Inc.
  • Sinopharm Group Co. Ltd.
  • Valneva SE
  • Serum Institute of India Pvt. Ltd.
  • Johnson & Johnson Services, Inc.
  • Bharat BIoTech
  • Regeneron Pharmaceuticals Inc.

第 10 章 分析师观点

• 兴衰
• 一致的机会地图

第 11 章 参考文献与调查方法

• 参考
• 调查方法

Global Preventive Vaccines Market is estimated to be valued at USD 55.41 Bn in 2025 and is expected to reach USD 107.35 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.9% from 2025 to 2032.

Figure. Preventive Vaccines Market Share (%), By Region 2025

The global preventive vaccines market is witnessing a period of growth owing to the rising burden of various infectious diseases across the world. Preventive vaccines are biological preparations that enhance immunity against certain diseases and help prevent future infections. Over the years, various advancements in vaccinology have enabled the development of immunization to safeguard individuals from life-threatening illnesses. Moreover, growing awareness regarding immunization and continuous innovation in vaccine technologies are fueling the demand for preventive vaccines. Governments of several countries have implemented national immunization programs to promote vaccination coverage. Rising healthcare expenditures on communicable diseases from public and private sources are also contributing to the expansion of the preventive vaccines market. However, high research and development costs involved in new vaccine development and lack of awareness in low-income nations are some of the factors hindering the market growth.

Market Dynamics:

The global preventive vaccines market growth is primarily driven by the increasing prevalence of target infectious diseases. Significant unmet medical needs associated with bacterial and viral infections across the emerging nations are driving the demand for immunization and vaccination programs. Various initiatives taken by governments and non-profit organizations to strengthen national immunization programs have augmented the uptake of preventive vaccines. For instance, the National Immunization Program of India aims to provide vaccines against 12 life-threatening diseases free of cost. Technological advancements in vaccine product development with improved immunogenicity and stability have unlocked new growth opportunities. However, high costs associated with new vaccine R&D, testing, clinical trials, and production are expected to restrain the market expansion to some extent during the forecast period. Rising focus on development of combination vaccines to lower vaccination costs offers lucrative opportunities in the forthcoming years.

Key Features of the Study:

• This report provides in-depth analysis of the global preventive vaccines market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global preventive vaccines market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study Sanofi, Pfizer Inc., Merck & Co. Inc., GSK plc., Takeda Pharmaceutical Company Limited, AstraZeneca, Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc., Novavax Inc., Zydus Group, Moderna, Inc., Sinopharm Group Co. Ltd., Valneva SE, Serum Institute of India Pvt. Ltd., Johnson & Johnson Services, Inc., Bharat Biotech, and Regeneron Pharmaceuticals Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global preventive vaccines market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global preventive vaccines market.

Detailed Segmentation-

• By Vaccine Type:
  • Live/Attenuated Vaccines
  • Inactivated Vaccines
  • Subunit Vaccines
  • Toxoid Vaccines
  • Others
• By Disease Type:
  • Pneumococcal
  • Poliovirus
  • Hepatitis
  • Influenza
  • Measles
  • Rubella
  • Others
• By Distribution Channel:
  • Public
  • Private
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Sanofi
  • Pfizer Inc.
  • Merck & Co. Inc.
  • GSK plc.
  • Takeda Pharmaceutical Company Limited
  • AstraZeneca
  • Daiichi Sankyo Co. Ltd.
  • Emergent BioSolutions Inc.
  • Novavax Inc.
  • Zydus Group
  • Moderna, Inc.
  • Sinopharm Group Co. Ltd.
  • Valneva SE
  • Serum Institute of India Pvt. Ltd.
  • Johnson & Johnson Services, Inc.
  • Bharat Biotech
  • Regeneron Pharmaceuticals Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Vaccine Type
  • Market Snapshot, By Disease Type
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Pipeline Analysis
• Epidemiology
• Pricing and Brand Analysis
• Manufacturer Revenue
• Acquisitions and Partnerships Scenario
• Product Launches/Approvals
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Preventive Vaccines Market- Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the market

5. Global Preventive Vaccines Market, By Vaccine Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Live/Attenuated Vaccines
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Inactivated Vaccines
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Subunit Vaccines
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Toxoid Vaccines
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Preventive Vaccines Market, By Disease Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Pneumococcal
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Poliovirus
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Hepatitis
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Influenza
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Measles
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Rubella
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Preventive Vaccines Market, By Distribution Channel, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Public
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Private
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Preventive Vaccines Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Regions, 2020-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • Sanofi
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Merck & Co. Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • GSK plc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Takeda Pharmaceutical Company Limited
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • AstraZeneca
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Daiichi Sankyo Co. Ltd.
  • Emergent BioSolutions Inc.
  • Novavax Inc.
  • Zydus Group
  • Moderna, Inc.
  • Sinopharm Group Co. Ltd.
  • Valneva SE
  • Serum Institute of India Pvt. Ltd.
  • Johnson & Johnson Services, Inc.
  • Bharat Biotech
  • Regeneron Pharmaceuticals Inc.

10. Analyst View

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact